Loading...
Market
What will be the next significant regulatory milestone for JYB1904 (RPT904) by December 31, 2025?
2
Resolution / Starting Odds
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
No significant milestone • 25%
Official announcements from RAPT Therapeutics or regulatory agencies
Story
RAPT Therapeutics Announces $150 Million Private Placement at $0.85/Share, 90.4% Pre-Market Surge, and License Agreement with Shanghai Jemincare
Dec 23, 2024, 01:31 PM
RAPT Therapeutics has announced a $150 million private placement, which includes 176.5 million shares and warrants priced at $0.85 per share. The company also entered an exclusive license agreement with Shanghai Jemincare for its novel long-acting anti-IgE antibody, JYB1904 (RPT904). Under this agreement, RAPT will retain worldwide rights to the drug, excluding mainland China, Hong Kong, Macau, and Taiwan. Jemincare will receive a $35 million upfront payment and could earn up to $672.5 million in milestone payments. Following these announcements, RAPT's stock experienced a significant pre-market increase of 90.4% and was up 74% during trading hours.
View original story
Similar markets
Positive results • 25%
Negative results • 25%
Mixed results • 25%
No results announced • 25%
FDA Approval • 25%
EMA Approval • 25%
Additional Phase 3 Trials • 25%
Other • 25%
Only in the US • 25%
Only in the EU • 25%
In both US and EU • 25%
In US, EU, and Japan • 25%
Approved • 33%
Rejected • 33%
Request for more data • 34%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
Yes • 50%
No • 50%
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%
Yes • 50%
No • 50%
European Medicines Agency (EMA) • 25%
Health Canada • 25%
Japan's PMDA • 25%
Other • 25%
Accelerated Approval • 25%
Full Approval • 25%
Conditional Approval • 25%
No Approval • 25%
